Cerba HealthCare SAS has agreed to purchase a minority stake in Groupe Bio7 from private equity firm Ardian.
Based in France, Cerba is a clinical pathology laboratory operator, while Groupe Bio7, also based in France, is an operator of clinical pathology laboratories across France.
Goodwin Procter LLP has been appointed as legal advisor to Cerba, while Latham & Watkins LLP and Hottinguer Corporate Finance have been appointed as legal and financial advisors respectively to Groupe Bio7 and Ardian.
Biotechnology company Innate Immunotherapeutics Ltd has agreed to acquire biopharmaceutical company Amplia Therapeutics Pty Ltd (Amplia).
Amplia shareholders will hold 45% of the ordinary shares of Innate following the acquisition.
Amplia has in-licensed two Focal Adhesion Kinase (FAK)-targeting drug candidates AMP886 and AMP945 from Cancer Research UK’s subsidiary Cancer Research Technology Limited.
Both companies involved in the deal are based in Australia.
The acquisition will enable Innate to focus on immuno-oncology and anti-cancer therapies and provide the company with access to Amplia’s FAK cancer programme.
US-based contract research organisation (CRO) Accelovance Inc has agreed to merge with Japanese CRO Linical Co Ltd.
Expected to be complete in June 2018, the merger will result in the creation of a market-leading global CRO operating across North America, Europe, and Asia-Pacific.
US-based biospecimens and related services provider BioIVT (formerly BioreclamationIVT) has acquired Ascendance Biotechnology for for $3.2m from AgeX Therapeutics Inc, a biotechnology company that is a subsidiary of BioTime Inc.
The target company is also based in the US and involved in the provision of cell-based assays for metabolite analysis. It was established through a merger of Hepregen Corporation and the ESI BIO products division of BioTime Inc in 2015.
The acquisition will expand BioIVT’s drug safety testing and toxicology portfolios.